The company is expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe.

Read this article to learn how a knitting club where students and staff got together to make hats for babies in need provided ...

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

As of January 31st, 2025, we held $12.9 million in cash compared to $3.5 million at the fiscal year-end 2024. This increase was driven by the successful execution of our ATM program, through which we ...

Pulse Biosciences, Inc. ( NASDAQ: PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of ...

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today ...

At least 14 million children are expected to face disruptions to essential nutrition support and services in 2025 because of ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...

If we want to turn these short-term gains into sustainable change, we must fully unleash the potential of methadone-assisted ...

A DNA nanomachine selectively targets skin cancer by detecting microRNA-7, activating phototherapy and releasing chemotherapy ...

Agency official says nearly 74,500 children may lose access to life-saving therapeutic food unless funds secured - Anadolu ...